针对 PI3K/AKT/mTOR 信号通路克服癌症耐药性。
Targeting PI3K/AKT/mTOR signaling to overcome drug resistance in cancer.
机构信息
Department of Oral and Maxillofacial Surgery, Center of Stomatology, Xiangya Hospital, Central South University, Changsha, China.
Department of Oral and Maxillofacial Surgery, Center of Stomatology, Xiangya Hospital, Central South University, Changsha, China; Institute of Oral Precancerous Lesions, Central South University, Changsha, China; Research Center of Oral and Maxillofacial Tumor, Xiangya Hospital, Central South University, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
出版信息
Chem Biol Interact. 2024 Jun 1;396:111055. doi: 10.1016/j.cbi.2024.111055. Epub 2024 May 17.
This review comprehensively explores the challenge of drug resistance in cancer by focusing on the pivotal PI3K/AKT/mTOR pathway, elucidating its role in oncogenesis and resistance mechanisms across various cancer types. It meticulously examines the diverse mechanisms underlying resistance, including genetic mutations, feedback loops, and microenvironmental factors, while also discussing the associated resistance patterns. Evaluating current therapeutic strategies targeting this pathway, the article highlights the hurdles encountered in drug development and clinical trials. Innovative approaches to overcome resistance, such as combination therapies and precision medicine, are critically analyzed, alongside discussions on emerging therapies like immunotherapy and molecularly targeted agents. Overall, this comprehensive review not only sheds light on the complexities of resistance in cancer but also provides a roadmap for advancing cancer treatment.
本文全面探讨了癌症耐药性这一挑战，重点关注关键的 PI3K/AKT/mTOR 通路，阐明其在各种癌症类型中的致癌作用和耐药机制。文中详细研究了耐药背后的多种机制，包括遗传突变、反馈回路和微环境因素，同时还讨论了相关的耐药模式。评估了针对该通路的当前治疗策略，本文强调了药物开发和临床试验中遇到的障碍。文中还批判性地分析了克服耐药性的创新方法，如联合疗法和精准医学，以及讨论了免疫疗法和分子靶向药物等新兴疗法。总的来说，这篇全面的综述不仅揭示了癌症耐药性的复杂性，还为推进癌症治疗提供了路线图。
Zotero 插件